Welcome to our dedicated page for Scilex Holding Co SEC filings (Ticker: SCLX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Scilex Holding Company filings document the regulatory record for an operating biopharmaceutical company with Nasdaq-listed common stock and warrants. Its disclosures cover material-event reports, material agreements, capital-structure matters, security-holder rights, clinical or regulatory updates, operating and financial results and risk-related information connected to its non-opioid pain management products and development activities.
Scilex proxy materials address annual meeting votes, director elections, auditor ratification and amendments to the company’s equity incentive plan. Other filings include Regulation FD and 8-K disclosures, preferred-stock and warrant-related security structure matters, legal-proceeding disclosures and reporting-status items such as notifications tied to annual-report timing and financial-statement preparation.
Scilex Holding Co director and CFO Stephen Hoi Ma reported an open-market purchase of 650,000 warrants. Each warrant was bought at $0.1538 and gives the right to buy one share of common stock at an exercise price of $1.20 per share.
The warrants were acquired on April 17, 2026 and are scheduled to expire on June 18, 2029. Following this transaction, Ma holds 650,000 warrants, each exercisable for one share of Scilex common stock.
Scilex Holding Co executive Henry Ji reported mixed warrant trades. On April 16, 2026, he made an open-market purchase of 3,250,000 warrants at $0.1538 per warrant, each exercisable at $1.20 for common stock. On April 17, 2026, he sold 650,000 warrants at the same price, leaving 2,600,000 warrants held directly, expiring on June 18, 2029.
Scilex Holding Company filed a Form S-3 to register up to $500,000,000 of securities on a shelf. The shelf prospectus permits offers of common stock, preferred stock, debt securities, warrants, rights and units in one or more offerings. The document describes existing commercial products (ZTlido, ELYXYB, GLOPERBA), pipeline assets (SP-102, SP-103, SP-104), certain corporate history and governance provisions, and states proceeds are intended for working capital and general corporate purposes.
Scilex Holding Company reports on a business focused on non-opioid pain management while outlining a major shift in its balance sheet strategy toward cryptocurrencies. The company currently markets three U.S. products: ZTlido for postherpetic neuralgia, ELYXYB for acute migraine, and GLOPERBA for prophylaxis of gout flares.
Its pipeline includes SEMDEXA (SP-102) for sciatica, SP-103 for acute low back and neck pain, and SP-104 for fibromyalgia, several with FDA fast track designations or completed Phase 3 or Phase 2 studies. Scilex also plans to adopt a cryptocurrency treasury strategy emphasizing bitcoin, Ethereum, BNB, Doge and similar assets as a principal long-term reserve, using third-party custodians and advisors, and potentially raising capital specifically to expand these holdings.
Scilex Holding Company notified the SEC that it cannot file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025 by the prescribed due date of March 31, 2026 because it needs additional time to finalize financial statements, including the consolidation of Vivasor Holding Company. The company anticipates filing the Form 10-K on or before April 15, 2026.
Scilex Holding Company filed a prospectus supplement registering up to 6,685,714 shares of Common Stock (aggregate of multiple tranches, including warrants and shares issuable upon exercise) as an update to prospectuses dated May 13, 2025.
The supplement attaches Current Reports on Form 8-K that disclose several corporate actions: a $20.0 million convertible note to Q Scan that converted into 140,379,226 Q Scan shares and a related agreement to purchase 193,021,436 Q Scan shares for approximately $27.5 million; elimination of the previously designated 5,000,000 Series 1 Mandatory Exchangeable Preferred Stock; and a Warrant Agreement with Oramed issuing a 100,000-warrant issuance (the "February 2026 Warrant") exercisable at an initial price of $20.00, subject to adjustment, with a 4.99% beneficial ownership cap (adjustable to 9.99% with notice) and an expiration of December 13, 2029. The supplement notes a 1-for-35 reverse stock split effective April 15, 2025 and reports last reported share and warrant prices as of February 19, 2026 of $8.01 and $0.15, respectively.
Scilex Holding Company files a prospectus supplement updating prior prospectuses and registering up to 6,685,714 shares of Common Stock and related instruments.
The supplement incorporates three Current Reports on Form 8-K dated January 29, 2026, February 2, 2026 and February 19, 2026, and attaches them to the prospectus. It discloses a $20.0 million convertible loan to Q Scan that converted into 140,379,226 Q Scan shares and a related stock purchase agreement to buy 193,021,436 Q Scan shares for approximately $27.5 million. It also describes a Warrant Agreement with Oramed that issued 100,000 warrants at an initial exercise price of $20.00 per share (floor price $8.22), exercisable through December 13, 2029, with a 4.99% beneficial ownership exercise cap (adjustable up to 9.99% with notice).
Scilex Holding Company files a prospectus supplement that updates multiple registration statements to register up to 6,685,714 shares of common stock and related instruments.
The supplement incorporates three prospectuses and attaches Current Reports on Form 8-K dated February 2, 2026 and February 19, 2026. It discloses a $20.0 million convertible note to Q Scan that converted into Q Scan common stock, a pending Stock Purchase of 193,021,436 Q Scan shares for approximately $27.5 million, revocation and elimination of a previously designated 5,000,000 share Series 1 preferred designation, and a Warrant Agreement with Oramed issuing a 100,000-warrant instrument exercisable at $20.00 (floor adjustment $8.22) expiring December 13, 2029.